These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

538 related articles for article (PubMed ID: 23439744)

  • 41. Effects of add-on treatment with sitagliptin on narrowing the range of glucose fluctuations in Japanese type 2 diabetes patients receiving insulin therapy.
    Mori Y; Taniguchi Y; Miyazaki S; Yokoyama J; Utsunomiya K
    Diabetes Technol Ther; 2013 Mar; 15(3):237-40. PubMed ID: 23402316
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach.
    Xu L; Man CD; Charbonnel B; Meninger G; Davies MJ; Williams-Herman D; Cobelli C; Stein PP
    Diabetes Obes Metab; 2008 Dec; 10(12):1212-20. PubMed ID: 18476982
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacokinetic and pharmacodynamic evaluation of sitagliptin plus metformin.
    Scheen AJ
    Expert Opin Drug Metab Toxicol; 2010 Oct; 6(10):1265-76. PubMed ID: 20707611
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and safety of adding pioglitazone or sitagliptin to patients with type 2 diabetes insufficiently controlled with metformin and a sulfonylurea.
    Liu SC; Chien KL; Wang CH; Chen WC; Leung CH
    Endocr Pract; 2013; 19(6):980-8. PubMed ID: 23807528
    [TBL] [Abstract][Full Text] [Related]  

  • 45. New treatments for type 2 diabetes mellitus: combined therapy with sitagliptin.
    Gagliardino JJ; Santoro S; Arellano S; Di Girolamo G
    Expert Opin Pharmacother; 2008 Jun; 9(9):1495-507. PubMed ID: 18518780
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes.
    Vilsbøll T; Rosenstock J; Yki-Järvinen H; Cefalu WT; Chen Y; Luo E; Musser B; Andryuk PJ; Ling Y; Kaufman KD; Amatruda JM; Engel SS; Katz L
    Diabetes Obes Metab; 2010 Feb; 12(2):167-77. PubMed ID: 20092585
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sitagliptin phosphate: a DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.
    Zerilli T; Pyon EY
    Clin Ther; 2007 Dec; 29(12):2614-34. PubMed ID: 18201579
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Sitagliptin: a novel agent for the management of type 2 diabetes mellitus.
    Pham DQ; Nogid A; Plakogiannis R
    Am J Health Syst Pharm; 2008 Mar; 65(6):521-31. PubMed ID: 18319497
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Add-on therapy with the DPP-4 inhibitor sitagliptin improves glycemic control in insulin-treated Japanese patients with type 2 diabetes mellitus.
    Katsuno T; Ikeda H; Ida K; Miyagawa J; Namba M
    Endocr J; 2013; 60(6):733-42. PubMed ID: 23386390
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and safety of insulin glargine added to a fixed-dose combination of metformin and a dipeptidyl peptidase-4 inhibitor: results of the GOLD observational study.
    Seufert J; Pegelow K; Bramlage P
    Vasc Health Risk Manag; 2013; 9():711-7. PubMed ID: 24259985
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sitagliptin added to previously taken antidiabetic agents on insulin resistance and lipid profile: a 2-year study evaluation.
    Derosa G; Ragonesi PD; Fogari E; Cicero AF; Bianchi L; Bonaventura A; Romano D; Maffioli P
    Fundam Clin Pharmacol; 2014 Apr; 28(2):221-9. PubMed ID: 23039403
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The effects of dipeptidyl peptidase-4 inhibitors in treatment of obese patients with type 2 diabetes.
    Velija-Asimi Z; Izetbegovic S; Karamehic J; Coric J; Panjeta M; Macic-Dzankovic A; Djelilovic-Vranic J; Dizdarevic-Bostandzic A
    Med Arch; 2013; 67(5):365-7. PubMed ID: 24601174
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Sitagliptin + metformin: new combination. Do not use this combination. Sitagliptin provides a slight increase of glucose-lowering effects, but there is a disturbing potential for long-term adverse effects: infections, depression, and cancer.
    Prescrire Int; 2009 Jun; 18(101):115. PubMed ID: 19637427
    [No Abstract]   [Full Text] [Related]  

  • 54. A comparative study of the effects of a dipeptidyl peptidase-IV inhibitor and sulfonylurea on glucose variability in patients with type 2 diabetes with inadequate glycemic control on metformin.
    Kim HS; Shin JA; Lee SH; Kim ES; Cho JH; Son HY; Yoon KH
    Diabetes Technol Ther; 2013 Oct; 15(10):810-6. PubMed ID: 24050737
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes.
    Yang W; Guan Y; Shentu Y; Li Z; Johnson-Levonas AO; Engel SS; Kaufman KD; Goldstein BJ; Alba M
    J Diabetes; 2012 Sep; 4(3):227-37. PubMed ID: 22672586
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Managed care perspective on three new agents for type 2 diabetes.
    VanDeKoppel S; Choe HM; Sweet BV
    J Manag Care Pharm; 2008 May; 14(4):363-80. PubMed ID: 18500914
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sitagliptin.
    Lyseng-Williamson KA
    Drugs; 2007; 67(4):587-97. PubMed ID: 17352516
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study.
    Seck T; Nauck M; Sheng D; Sunga S; Davies MJ; Stein PP; Kaufman KD; Amatruda JM;
    Int J Clin Pract; 2010 Apr; 64(5):562-76. PubMed ID: 20456211
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition.
    Rizzo MR; Barbieri M; Marfella R; Paolisso G
    Diabetes Care; 2012 Oct; 35(10):2076-82. PubMed ID: 22688551
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy and safety of sitagliptin as add-on therapy on glycemic control and blood glucose fluctuation in Japanese type 2 diabetes subjects ongoing with multiple daily insulin injections therapy.
    Shimoda S; Iwashita S; Ichimori S; Matsuo Y; Goto R; Maeda T; Matsuo T; Sekigami T; Kawashima J; Kondo T; Matsumura T; Motoshima H; Furukawa N; Nishida K; Araki E
    Endocr J; 2013; 60(10):1207-14. PubMed ID: 23912974
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.